争霸8官方入口

争霸8官方入口:争霸8官方入口

College of Biological Science and Engineering

陈雄*

发布日期:2023-06-26 发布者:

姓名:陈雄

性别:

职务:主任/博士生导师

学历:博士


电子邮件:

zpccx81@163.com

主要研究方向:实体肿瘤人工智能诊疗

教育工作经历:

1. 202212-至今,争霸8官方入口孟超医学与交叉科学中心,硕士生导师

2. 202212-至今,福建医科大学孟超肝胆医院肿瘤医学中心,科主任/主任医师

3. 201812-202212月,联勤保障部队第九〇〇医院肿瘤科,科主任助理/副主任医师

4. 201712-201806月,美国凯斯西储大学,国家留学基金委公派访问学者

5. 201312-201810月,南京军区福州总医院肿瘤科,科主任助理/副主任医师

6. 201107-201312月,南京军区福州总医院肿瘤科,主治医师

7. 200909-201008月,日本京都大学,笹川医学奖学金资助研修生

8. 200509-201106月,第四军医大学,内科学,硕士、博士

9. 200107-200509月,南京军区福州总医院肿瘤科,住院医师

10. 199609-200106月,第一军医大学,临床医学,学士


教学简介:

科研简介:主要从事实体肿瘤与人工智能交叉领域的应用研究,包括常见恶性肿瘤诊断与治疗的新方法与新策略、基于多模态深度学习技术的肝癌治疗动态监测系统、通过医学影像大数据分析实现肿瘤患者的全生命周期的智慧管理等。先后主持国家自然科学基金项目1项,省部级项目4项,院级科研启动资金1项。已在EClinicalMedicine、Cancer Science、Frontiers in Pharmacology、Journal of Hepatocellular Carcinoma等国际权威学术期刊发表SCI论文二十余篇,单篇最高影响因子17.033。获福建省科技进步奖2项。2021年入选福建省百千万人才工程人选。

社会兼职:Frontiers in oncology 副主编。中国抗癌协会肿瘤分子医学专业委员会常务委员、中国抗癌协会整合肿瘤专业委员会委员、中国抗癌协会神经内分泌肿瘤专业委员会委员、中国抗癌协会第一届多原发和不明原发肿瘤专业委员会委员、中国南方肿瘤临床研究协会肺癌专业委员会委员、福建省抗癌协会癌症康复与姑息治疗专业委员会常务委员、福建省抗癌协会肿瘤免疫治疗专业委员会委员、福建省抗癌协会肿瘤内科专业青年委员会副主任委员。

科研项目:

1.CacyBP/SIP通过ERK1/2调控PHD2-pVHL-HIF1α信号通路促进胰腺癌转移的分子机制研究,福建省自然科学基金面上项目,2020/11-2023/02,主持。

2.基于多模态深度学习技术动态预测不可切除肝癌免疫治疗死亡风险的研究,科研启动资金,2023/01-2025/12,主持。

3CacyBP/SIP-ERK1/2-NFAT信号轴介导胰腺癌免疫逃逸的机制研究,福建省科技创新联合资金项目,2017/12-2020/12,主持。

4CacyBP/SIP通过NFAT上调FasL介导胰腺癌免疫逃逸的分子机制,福建省自然科学基金面上项目,2016/04-2019/03,主持。

5CacyBP/SIP 调控RhoA 促进胰腺癌转移的分子机制研究,国家自然科学基金青年基金项目,2014/01-2016/12,主持。

6CacyBP/SIP促进胰腺癌转移的分子机制研究,福建省自然科学基金青年基金项目,2012/04-2015/03,主持。

已发表论文:(*为通讯作者)

(1) LU L, SHEN L, WU Z, SHI Y, HOU P, XUE Z, LIN C, CHEN X*. Trajectories of serum α-fetoprotein and intermediate-stage hepatocellular carcinoma outcomes after transarterial chemoembolization: A longitudinal, retrospective, multicentre, cohort study. EClinicalMedicine [J].2022 Apr 16;47:101391.(影响因子17.033)

(2) Lin Y, Yu X, Lu L, Chen H, Wu J, Chen Y, Lin Q, Wang X, Chen X, Chen X*. Age is a significant biomarker for the selection of neoadjuvant chemotherapy plus radiotherapy versus concurrent chemoradiotherapy in patients with advanced nasopharyngeal carcinoma. Cancer Biomark. 2023 Mar 7.(影响因子3.828)

(3) SU Z, LU L, CHEN F, CHEN J, CHEN X*. Gut Microbiota and Sunitinib-Induced Diarrhea in Metastatic Renal Cell Carcinoma: A Pilot Study. Cancer Manag Res [J]2021 Nov 20;13:8663-8672.(影响因子3.602)

(4) LU L, ZHENG P, WU Z, CHEN X*. Hepatic Resection Versus Transarterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: A Cohort Study. Front Oncol [J].2021 Oct 27;11:618937.(影响因子 5.738)

(5) Wang X, Wang Z, Chen Y, Lin Q, Chen H, Lin Y, Lu L, Zheng P, Chen X*. Impact of prior cancer on the overall survival of patients with nasopharyngeal carcinoma. Am J Otolaryngol[J]. 2022 Jan-Feb;43(1): 103235. (影响因子2.873)

(6) Lin Q, Lu L, Wang X, Lin Y, Chen Y, Chen H, Chen S, Lin S, Zhang Y, Zheng P, Chen X*. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus neoadjuvant chemotherapy plus concurrent chemoradiotherapy for ascending or descending types of nasopharyngeal carcinoma: A retrospective study[J]. Am J Otolaryngol. 2022 Jan-Feb;43(1):103193.(影响因子2.873)

(7) LU L, SU Z, ZHENG P, WU Z, ZHANG Y, HE H, LIU J, LIN S, CHEN X*. Association between platelet count and hepatocellular carcinoma overall survival: a large retrospective cohort study. BMJ Open [J]2020 Nov 6;10(11):e038172.(影响因子3.006)

(8) LU L, ZHANG Y, ZHENG P, WU Z, WANG X, CHEN Y, CHEN X*. Elevated Platelet Count is Associated with Poor Survival After Transarterial Chemoembolization Treatment in Patients with Hepatocellular Carcinoma: A Cohort Study. J Hepatocell Carcinoma [J], 2020 Oct15;7:191-199.(影响因子4.962

(9) WANG X, WU S, CHEN Y, SHAO E, ZHUANG T, LU L, CHEN X*. Fatal Adverse Events Associated With Programmed Cell Death Ligand 1 Inhibitors: A Systematic Review and Meta-Analysis. Front Pharmacol [J],2020 Jan 31;11:5.(影响因子5.988)

(10) Zheng P, Chen X, Xie J, Chen X, Lin S, Ye L, Chen L, Lin J, Yu X, Zheng M. Capn4 is induced by and required for LMP1 promotion of nasopharyngeal carcinoma metastasis through ERK/AP-1 signaling. Cancer Sci. 2019 Nov 5. (影响因子6.518)

(11) Lu L, Zhuang T, Shao E, Liu Y, He H, Shu Z, Huang Y, Yao Y, Lin S, Lin S, Chen X, Chen X*. Association of antibiotic exposure with the mortality in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy: A hospital-based retrospective cohort study. PLoS One. 2019 Sep 10;14(9):e0221964. (影响因子3.752)

(12) Huang Y, Zheng J, Tan T, Song L, Huang S, Zhang Y, Lin L, Liu J, Zheng P, Chen X*, Chen X, Ouyang X: BTG1 low expression in pancreatic ductal adenocarcinoma is associated with a poorer prognosis. Int. J. Biol. Markers, 2017. (影响因子3.248)

(13) Yu R, Li C, Lin X, Chen Q, Li J, Song L, Lin L, Liu J, Zhang Y, Kong W, Ouyang X, Chen X*: Clinicopathologic features and prognostic implications of MYBL2 protein expression in pancreatic ductal adenocarcinoma..Pathol. Res. Pract., 2017, 213(8): 964-968. (影响因子3.309)

(14) Yin Y, Zhu X, Huang S, Zheng J, Zhang M, Kong W, Chen Q, Zhang Y, Chen X* Lin K, Ouyang X: Expression and clinical significance of placenta-specific 1 in pancreatic ductal adenocarcinoma. Tumour Biol., 2017, 39(6): 1010428317699131.

(15) HUANG S, CHEN X, ZHENG J, HUANG Y, SONG L, YIN Y, XIONG J. Low SIRT3 expression contributes to tumor progression, development and poor prognosis in human pancreatic carcinoma. Pathol Res Pract [J], 2017 Nov;213(11):1419-1423.(影响因子3.309

(16) Zheng J, Huang S, Huang Y, Song L, Yin Y, Kong W, Chen X*, Ouyang X: Expression and prognosis value of SHP2 in patients with pancreatic ductal adenocarcinoma. Tumour Biol 2016; 37: 7853-7859.

(17) Huang S, Zheng J, Huang Y, Song L, Yin Y, Ou D, He S, Chen X*, Ouyang X*: Impact of S100A4 expression on clinicopathological characteristics and prognosis in pancreatic cancer: A Meta-Analysis. DIS MARKERS 2016;2016:8137378. (影响因子3.464)

(18) ZHENG P C, CHEN X, ZHU H W, ZHENG W, MAO L H, LIN C, LIU J N, ZHENG M. Capn4 is a marker of poor clinical outcomes and promotes nasopharyngeal carcinoma metastasis via nuclear factor-κB-induced matrix metalloproteinase 2 expression. Cancer Sci [J], 2014 Jun;105(6):630-8.(影响因子6.518

(19) Chen X*, Zheng P, Xue Z, Li J, Wang W, Chen X, Xie F, Yu Z, Ouyang X *. CacyBP/SIP enhances multidrug resistance of pancreatic cancer cells by regulation of P-gp and Bcl-2. Apoptosis. 2013 Jul; 18(7):861-9. (影响因子5.561)

(20) Chen X*, Li X, Chen J, Zheng P, Huang S, Ouyang X*. Over-expression of CIAPIN1 inhibited pancreatic cancer cell proliferation and was associated with good prognosis in pancreatic cancer. Cancer Gene Ther. 2012 Aug; 19(8):538-44. (影响因子5.854)

(21) Chen X, Mo P, Li X, Zheng P, Zhao L, Xue Z, Ren G, Han G, Wang X, Fan D*. CacyBP/SIP protein promotes proliferation and G1/S transition of human pancreatic cancer cells. Mol Carcinog. 2011 Oct; 50(10):804-10. (影响因子5.139)

(22) Chen X, Han G, Zhai H, Zhang F, Wang J, Li X, Huang S, Wang X, Fan D. Expression and Clinical Significance of CacyBP/SIP in Pancreatic Cancer. Pancreatology. 2008; 8(4-5):4707. (影响因子3.977)


获奖情况

1. 2021年获福建省百千万人才工程人选

2. 2020年获福建省科技进步奖二等奖,排名第1

3. 2017年获福建省科技进步奖三等奖,排名第2

4. 2016年荣立军队个人三等功


争霸8官方入口官方(中国)官方网站IOS/安卓通用版/手机APP